May 12, 2016 6:11 PM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
SunTrust Robinson Humphrey analyst, Sandy Draper, responding to
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
(NASDAQ: WBMD)'s first-quarter earnings report, upgraded the stock from Neutral to Buy Thursday morning."We see the positive biopharma market growth as a sustainable tailwind to drive double-digit top line and high teens EBITDA growth for 3-5 years," Draper said."WebMD has demonstrated that it is a demand-driven model with ad-revenue in 1Q16 growing at 15.7% y/y, which far outpaced the 4% growth in page-view traffic observed over the same time frame. We reason that the incremental benefit of additional page-view traffic is less important to drive revenue growth given WBMD ranks number one in unique visitors (about 50% more than nearest competitor), page views (2.5x nearest competitor) and time spent on the website by a wide margin," according to the SunTrust analyst. Amid increased sales estimates, Draper boosted her price target on WebMD shares from $57 to $75.Although volatile over the course of Thursday's session, the stock closed up a moderate 0.85 percent at $63.29 Thursday. Draper's new price target represents potential upside of about 19 percent.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.